Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Parabilis Medicines initiated a dose-ranging clinical cohort of zolucatetide in familial adenomatous polyposis as part of its ongoing Phase 1/2 trial. Early proof-of-concept data showed significant reductions in duodenal polyp burden in two FAP patients — from Spigelman Stage IV to near-normal and Stage II to Stage I — with a favorable safety profile to date.
Key figures
- Drug Name
- zolucatetide
- Phase Of Trial
- Phase 1/2
- Trial id
- NCT05919264
- Next data catalyst
- additional FAP/desmoid data expected Q1 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.